Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 307

Similar articles for PubMed (Select 18184521)

1.

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ.

Clin Nephrol. 2007 Dec;68(6):386-91.

PMID:
18184521
2.

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.

Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N.

Nephrol Dial Transplant. 2009 Dec;24(12):3794-9. doi: 10.1093/ndt/gfp372. Epub 2009 Aug 7.

3.

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1125-30. doi: 10.2215/CJN.05161107. Epub 2008 May 1.

4.

A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.

Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S.

Am J Kidney Dis. 2010 Feb;55(2):307-15. doi: 10.1053/j.ajkd.2009.10.051. Epub 2009 Dec 30.

PMID:
20042256
5.

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.

Nephrol Dial Transplant. 2009 Jan;24(1):278-85. doi: 10.1093/ndt/gfn488. Epub 2008 Sep 27.

6.

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

Pai AB, Shepler BM.

Pharmacotherapy. 2009 May;29(5):554-61. doi: 10.1592/phco.29.5.554. Review.

PMID:
19397463
7.

Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.

Katopodis KP, Andrikos EK, Gouva CD, Bairaktari ET, Nikolopoulos PM, Takouli LK, Tzallas CS, Elisaf MS, Pappas MV, Siamopoulos KC.

Perit Dial Int. 2006 May-Jun;26(3):320-7.

8.

Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.

Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R.

Clin Nephrol. 2009 Oct;72(4):252-8.

PMID:
19825330
9.

Sevelamer worsens metabolic acidosis in hemodialysis patients.

De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E, Iacono G, Ciacci C, Savica V, Cirillo M.

J Nephrol. 2006 Mar-Apr;19 Suppl 9:S108-14.

PMID:
16736432
10.

Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.

Hamida FB, Fatma LB, Barbouch S, Kaaroud H, Helal I, Hedri H, Abdallah TB, Maiz HB, Kheder A.

Saudi J Kidney Dis Transpl. 2008 Mar;19(2):183-8.

11.
12.

Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.

Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.

Saudi J Kidney Dis Transpl. 2012 Sep;23(5):934-8. doi: 10.4103/1319-2442.100865.

13.

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR.

Kidney Int. 2004 May;65(5):1914-26.

PMID:
15086935
14.

A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.

Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY, Lin PW, Liu JH, Liao PY, Huang CC.

Ren Fail. 2006;28(8):701-7.

PMID:
17162430
15.

Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.

Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, Akiba T, Nitta K.

Nephron Clin Pract. 2008;108(4):c278-83. doi: 10.1159/000127361. Epub 2008 Apr 22.

PMID:
18434749
16.

Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.

Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T; Research Group for Future Hemodialysis.

Ther Apher Dial. 2008 Apr;12(2):126-32. doi: 10.1111/j.1744-9987.2008.00557.x.

PMID:
18387160
17.

Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.

Ramos R, Moreso F, Borras M, Ponz E, Buades JM, Teixidó J, Morey A, Garcia C, Vera M, Doñate MT, de Arellano MR, Barbosa F, González MT.

Perit Dial Int. 2007 Nov-Dec;27(6):697-701.

18.

RenaGel efficacy in severe secondary hyperparathyroidism.

Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M.

Nefrologia. 2002;22(5):448-55.

PMID:
12497746
19.

Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.

Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF.

Nephrology (Carlton). 2006 Apr;11(2):142-6.

PMID:
16669977
20.

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.

Nephrol Dial Transplant. 2014 Jan;29(1):152-60. doi: 10.1093/ndt/gft232. Epub 2013 Oct 22.

PMID:
24151017
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk